2024
Real-World Evidence of Automated Insulin Delivery System Use
Considine E, Sherr J. Real-World Evidence of Automated Insulin Delivery System Use. Diabetes Technology & Therapeutics 2024, 26: 53-65. PMID: 38377315, PMCID: PMC10890954, DOI: 10.1089/dia.2023.0442.Peer-Reviewed Original ResearchConceptsGlucose management indicatorAid useRetrospective real-world studyMode of insulin deliveryGlycemic benefitsFollow-up periodTrial findingsFood and Drug AdministrationStandard of careReal-world studyInsulin deliveryType 1 diabetesNonpregnant individualsPivotal trialsRetrospective analysisPrimary outcomeHemoglobin A1cConclusion:</i></b>Drug AdministrationInclusion criteriaHbA1cGlycemic outcomesSystematic reviewResults:</i></b>Target range
2023
Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review
Jacobsen L, Sherr J, Considine E, Chen A, Peeling S, Hulsmans M, Charleer S, Urazbayeva M, Tosur M, Alamarie S, Redondo M, Hood K, Gottlieb P, Gillard P, Wong J, Hirsch I, Pratley R, Laffel L, Mathieu C. Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review. Communications Medicine 2023, 3: 132. PMID: 37794113, PMCID: PMC10550996, DOI: 10.1038/s43856-023-00358-x.Peer-Reviewed Original ResearchType 1 diabetesTreatment of peopleSystematic reviewAdvanced hybrid closed-loop systemBaseline glycemic levelsSelf-care burdenOptimization of outcomesContinuous glucose monitoring systemHybrid closed-loop systemAdvanced complicationsStandard careGlucose monitoring systemHypoglycemia riskGlycemic levelsGlycemic variabilityDiabetes therapyDiabetesHealthcare teamInsulin pumpType 1Glucose monitoringInsulin deliveryDevice initiationBehavioral modificationFurther studies